Confirmatory Study of DSP-5423P in Patients With Schizophrenia

NCT02287584 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

580

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: DSP-5423P Placebo
DRUG: DSP-5423P 40mg
DRUG: DSP-5423P 80mg
DRUG: DSP-5423P Placebo-to-Flex
DRUG: DSP-5423P Active-to-Flex

Sponsor

Sumitomo Pharma Co., Ltd.